how to avoid desk rejection at Lancet Neurology

Editors at Lancet Neurology are effectively running a fast triage on consequence and credibility. The screen usually takes less than five minutes and is based almost entirely on the abstract, cover letter, and first results figure, not on reading the full manuscript through. Authors who bury the clinical consequence in the discussion rather than stating it in the abstract lose the editorial read before reviewers are ever contacted.

The journal favors work that helps neurologists make better treatment, diagnostic, prognostic, or management decisions. A paper can be scientifically impressive and still feel too far from care delivery for this venue. The clinical relevance question must be answerable from the abstract alone, before the editor reaches the methods or discussion.

Neurology papers at this level need more than interesting signals. Editors look for endpoint choice, control strategy, sample quality, ascertainment, and follow-up design that can withstand immediate reviewer pressure. Papers that look clinically important but rest on fragile endpoint logic or underpowered comparisons typically fail the editorial screen before reviewers are asked.

The paper should matter beyond a narrow disease subgroup, one institution, or one heavily selected cohort. Even highly specialized neurology papers need a convincing broader consequence.

The title, abstract, figures, cover letter, and reporting details all matter. If the package feels overstated, under-reported, or imprecise, the desk decision usually gets harsher quickly.

This is why strong neurology papers can still die early here. The editors are not only asking whether the science is respectable. They are asking whether the paper looks like something neurologists across subspecialties should care about now. If the answer feels niche, speculative, or too method-heavy for the practical consequence, the journal often decides quickly.

• Submitting basic science, animal-model, or biomarker work without a clear bridge to clinical neurology.
• Using surrogate endpoints that do not convincingly map to a meaningful patient outcome.
• Presenting an underpowered cohort as if it supports a field-level conclusion.
• Framing a technically solid study as practice-changing when the actual clinical implication is modest.
• Using a single-center or highly selected sample without explaining why the result generalizes.
• Ignoring reporting expectations for trials, observational studies, or systematic reviews.
• Sending a cover letter that summarizes the abstract instead of arguing why the paper belongs in Lancet Neurology rather than JAMA Neurology, Brain, Neurology, or Annals of Neurology.

Another common trigger is a paper that reads as if the authors are still in love with the mechanism but have not fully translated the message for a clinically oriented editor. Lancet Neurology will publish technically serious work, but it still wants the clinical decision consequence to be visible.

The title, abstract, and first discussion paragraph should all make the same point: what clinical question is changed by this study? If the answer is buried, the manuscript looks less important than it may actually be.

Lancet Neurology readers care about outcomes that matter to patients and clinicians. If the paper leans on biomarkers, imaging, or surrogate endpoints, explain clearly why those measures should change behavior.

If the study population is narrow, heavily selected, or geographically concentrated, build the case for why the lesson still travels. Editors are quick to downgrade papers that feel too local or too niche.

Before submission, ask four blunt questions:

1. Would a practicing neurologist know why this matters after reading only the abstract?
2. Are the endpoints strong enough that a skeptical reviewer cannot dismiss the paper as surrogate-heavy?
3. Does the paper still look important if the novelty language is stripped away?
4. Is there a real reason this belongs in Lancet Neurology instead of a slightly narrower journal?

If those answers are shaky, the safest move is to fix the package before you submit.

You can usually tell when a paper is closer to the Lancet Neurology bar because the package behaves differently from the start:

• the title and abstract make the clinical consequence obvious
• the endpoint logic feels defensible without a long explanation
• the figures support a neurologist-facing message, not only a technical one
• the discussion does not need inflated novelty language to sound important
• the cover letter explains why the manuscript belongs here rather than at JAMA Neurology, Brain, Neurology, or Annals of Neurology

That matters because a lot of borderline submissions are not obviously bad. They are simply one step too narrow, one step too surrogate-driven, or one step too local for this editorial tier. The stronger the package is at answering those concerns before review, the lower the desk-rejection risk becomes.

One common mistake is assuming that any strong neurology paper with clinical data is naturally a Lancet Neurology paper. That is not how the journal thinks. Editors usually distinguish between:

• papers that refine specialty understanding
• papers that alter neurological practice or field-level judgment

The first group can still be excellent, but it often belongs somewhere else. The second group is what gets more editorial patience here. If your manuscript mainly improves a subspecialty conversation without broader neurology consequence, that is usually the fit problem you need to solve before submission.

The fastest self-check is this: if a general neurology editor would need extra explanation before seeing why the result changes field-level judgment, the fit is probably still too weak for this journal.

That usually means the paper should either sharpen its practical consequence or move to a journal whose audience is narrower and more specialized.

A Lancet Neurology desk-rejection risk check can flag the desk-rejection triggers covered above before your paper reaches the editor.

In our pre-submission review work with manuscripts targeting Lancet Neurology, three patterns generate the most consistent desk rejections worth knowing before submission.

Mechanistic or biomarker papers without a bridge to clinical neurology decisions.

According to Lancet Neurology's editorial criteria, the journal focuses on research that changes how neurologists practice, not on mechanistic studies without a clear patient-care consequence. We see this pattern in manuscripts we review more frequently than any other Lancet Neurology-specific failure. Papers that identify a pathway, biomarker, or imaging finding without demonstrating how the result would change a neurologist's diagnostic, treatment, or monitoring decision face desk rejection before reviewer recruitment begins. In our experience, roughly 50% of manuscripts we diagnose for Lancet Neurology have a translational gap between the biology demonstrated and the clinical practice consequence claimed.

Surrogate endpoints presented as if they change how neurologists treat patients.

Per SciRev community data on Lancet Neurology, roughly 50% of authors report a desk decision within two weeks, with surrogate endpoint reliance and overstated clinical consequence cited among the leading reasons for early rejection. We see this pattern in roughly 35% of Lancet Neurology manuscripts we review, where the paper reports improvement on an imaging marker, biomarker, or composite endpoint but the abstract and conclusions frame the finding as if it changes treatment decisions directly. In our experience, roughly 30% of Lancet Neurology manuscripts we diagnose have endpoint language that outpaces what the study design can actually demonstrate.

Cover letters summarizing the abstract without arguing for Lancet Neurology fit.

Editors consistently identify manuscripts where the cover letter describes the study design and primary results rather than arguing why this specific finding changes neurological practice in a way that justifies a Lancet-tier venue over JAMA Neurology, Brain, or a specialist neurology journal. The cover letter for a Lancet Neurology submission should make the practice-consequence case explicitly and explain why a broad neurological readership needs to see this paper now. Before submitting, a Lancet Neurology desk-rejection risk check identifies whether the framing meets the journal's practice-consequence bar.

Per SciRev community data on Lancet Neurology, roughly 50% of authors report a desk decision within two weeks. In our experience, roughly 40% of manuscripts we review for Lancet Neurology have clinical framing or endpoint issues that would substantially strengthen the submission with targeted revision before upload. In our broader diagnostic work with Lancet journals, roughly 45% of manuscripts that receive a major revision request are asked to strengthen the clinical consequence argument or address the generalizability of the primary endpoint more directly.